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Background: A previous study has suggested that drug price adjustments allow physicians in Taiwan to gain
greater profit by prescribing generic drugs. To better understand the effect of price adjustments on physician
choice, this study used renin-angiotensin drugs (including angiotensin-converting enzyme inhibitors [ACEIs] and
angiotensin receptor blockers [ARBs]) to examine the impact of price adjustments on utilization of and expenditures
on patented and off-patent drugs with the same therapeutic indication.
Methods: Using the Taiwan’s Longitudinal Health Insurance Database (2005), we identified 147,157 patients
received ACEIs and/or ARBs between 1997 and 2008. The annual incident and prevalent users of ACEIs, ARBs and
overall renin-angiotensin drugs were examined. Box-Tiao intervention analysis was applied to assess the impact of
price adjustments on monthly utilization of and expenditures on these drugs. ACEIs were divided into patented and
off-patent drugs, off-patent ACEIs were further divided into original brands and generics, and subgroup analyses
were performed.
Results: The number of incident renin-angiotensin drug users decreased over the study period. The number of
prevalent ARB users increased and exceeded the cumulative number of first-time renin-angiotensin drug users
starting on ARBs, implying that some patients switched from ACEIs to ARBs. After price adjustments, long term
trend increases in utilization were observed for patented ACEIs and ARBs; a long-term trend decrease was observed
for off-patent ACEIs; long-term trend change was not significant for overall renin-angiotensin drugs. Significant
long-term trend increases in expenditures were observed for patented ACEIs after price adjustment in 2007 (200.9%,
p = 0.0088) and in ARBs after price adjustments in 2001 (173.4%, p< 0.0001) and 2007 (146.3%, p< 0.0001). A
significant long-term trend decrease in expenditures was observed for off-patent ACEIs after 2004 price adjustment
(−156.9%, p< 0.0001). Expenditures on overall renin-angiotensin drugs showed long-term trend increases after price
adjustments in 2001 (72.2%, p< 0.0001) and 2007 (133.4%, p< 0.0001).
Conclusions: Price adjustments did not achieve long-term cost savings for overall renin-angiotensin drugs. Possible
switching from ACEIs to ARBs within individuals is evident. Policy makers should reconsider the appropriateness of
the current adjustment strategies applied to patented and off-patent drugs.
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Taiwan’s National Health Insurance (NHI) system is a
government-run, single-payer, compulsory program imple-
mented on March 1, 1995. The Bureau of National Health
Insurance (BNHI) is the executive organization of the NHI
program. This program has universal coverage, including
pharmaceuticals, ambulatory care, inpatient care, traditional
Chinese medicine, dental services, child delivery, rehabilita-
tion, home nursing care and chronic psychiatric rehabilita-
tion. Currently, it covers more than 99% of the population
(approximately 23 million people) [1].
The three main components of the NHI system are the
BNHI, the insured and the BNHI-contracted health care
providers. Funding for the BNHI comes from the insured
(38%), the employers (36%) and the government (26%). The
BNHI issues insurance cards to the insured and pays the
health care providers according to the services they provide,
including prescriptions listed in the Pharmaceutical Benefit
scheme (PBS). When the insured receive medical services
from BNHI-contracted health care providers, they only pay
the provider a registration fee as well as any co-payment for
outpatient services, inpatient services and drugs [1].
The BNHI established the PBS in 1996. It contains the
reimbursement principles, and a list of the reimbursed
products with a brand-specific reimbursement price for
each product. This reimbursement price is paid to physi-
cians, as they are responsible for purchasing, prescribing
and dispensing in Taiwan [2]. However, physicians can
purchase medications from pharmaceutical companies at
the market trading price with a discount on the PBS re-
imbursement price. A profit margin for physicians then
develops because of the difference between the reim-
bursement price and the market trading price; this is
known as drug price deviation. Figure 1 provides an ex-
ample of this pricing and payment structure. Under this
reimbursement structure, physicians’ prescribing deci-
sions have been hypothesized to be influenced by the
drug price deviation [3].
The NHI, like many health insurance programs, faces fi-
nancial challenges and its expenditures have exceeded its
revenue since 1998 [3]. Annual pharmaceutical expendi-
tures have doubled from 62.2 billion New Taiwan Dollars
(NT$; at an exchange rate of NT$30.39 to US$1 on June
30, 2008) in 1996 to NT$131.3 billion in 2010 [1], and the
BNHI is under pressure to control outlays. Stepwise price
adjustments (PA), which aim to reduce the reimbursement
price to be close to the market trading price, is the major
cost containment strategy adopted by the BNHI since 1996
[4]. In the early stage of price adjustments (1996–1997) re-
imbursement price adjustments were based on the prices
of international products or inter-brand comparison of
existing products. On April 1, 2000 (PA2000), the BNHI
began to conduct market price and volume surveys before
each price adjustment, and adjusted the reimbursementprice of each individual drug according to its weighted aver-
age market trading price (WAP) calculated from the market
survey. Above the WAP, the BNHI allows a reasonable
profit margin (known as the reasonable zone or “r-zone”)
for physicians. The “r-zone” for patented drugs has been
higher than that for off-patent drugs since November 1,
2006 (PA2006). Since April 1, 2001 (PA2001), the BNHI
has adopted different strategies for patented and off-patent
drugs. The reimbursement prices of patented drugs are still
adjusted based on the individual drug’s WAP, but those of
off-patent drugs are adjusted according to the principle of
“generic grouping”. Under this principle, drugs with the
same active ingredients, content, and strength are grouped
together; and their reimbursement prices are adjusted
according to a group weighted average price (GWAP) cal-
culated from their market trading prices. The Additional file
1 provides the details of the PBS and an example to illus-
trate the pricing structure.
Price adjustments based on the market price and vol-
ume survey and generic grouping have, from the BNHI’s
perspective, demonstrated cost savings in pharmaceutical
expenditures for all PBS listed drugs [5]. Liu et al. [6]
concluded that the financial incentive offered by the drug
price deviation is the major driving force for physicians
to switch from a branded drug to its generic version.
However, previous studies did not investigate the poten-
tial switching between patented and off-patent drugs
after price adjustments. It is critical to analyze whether
price adjustments result in prescription switching be-
tween these products, and whether that eventually leads
to the anticipated cost savings without compromising
patient safety and therapeutic effectiveness.
ACEIs (angiotensin-converting enzyme inhibitors) and
ARBs (angiotensin receptor blockers) both work through
the same renin-angiotensin pathway and have a similar
effect in cardiovascular disease and renal protection [7].
Because several ACEIs were launched in Taiwan before
1997, and their off-patent products heavily dominated
the market share over time, they provide an ideal ex-
ample for obtaining knowledge about the longitudinal
changes in medication utilization and expenditures
under stepwise price adjustments. Furthermore, because
ARBs are generally more expensive than ACEIs, but are
therapeutically similar to ACEIs, we are able to compare
the impact of price adjustments on the two classes.
Therefore, this study uses ACEIs and ARBs as examples
to examine the impact of Taiwan’s stepwise price adjust-
ments on utilization of and expenditures on patented
and off-patent drugs.
Methods
Study design and data source
This retrospective, observational study was based on a
cohort of patients treated with ACEIs and/or ARBs within
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Figure 1 PBS reimbursement price vs. market trading price: an example of a generic ACEI - Enalapril. ACEIs, angiotensin-converting
enzyme inhibitors; BNHI, Bureau of National Health Insurance; NT$, New Taiwan Dollars (at an exchange rate of NT$30.39 to US$1 on June 30,
2008); PBS, Pharmaceutical Benefit Scheme.
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Database 2005 (LHID2005) [8] contains all the original
claim data of one million beneficiaries randomly sampled
from the year 2005 Registry for Beneficiaries of the National
Health Insurance Research Database (NHIRD), which con-
tains registration data of everyone who was a beneficiary of
the NHI program during the period of January 1, 2005, to
January 1, 2006. The BNHI and the National Health Re-
search Institutes (NHRI) provided access to the LHID2005
(registered numbers: 98177 and 98251). Among the one
million randomly sampled individuals, clinical conditions
were identified based on the International Classification of
Disease Version 9 Clinical Modification (ICD9-CM) codes
and the A-codes used initially in Taiwan’s NHI program [9].
Utilization of and expenditures on drugs were determined
for inpatient and outpatient services at all BNHI-contracted
health settings and pharmacies.
Patient selection
Patients with at least one ATC code [10] for ACEIs (from
January 1997 to December 2008) or ARBs (from Febru-
ary 1998 to December 2008) were included and were
regarded as the whole sample in this study, defined as
renin-angiotensin drug users. These patients were fur-
ther classified into three groups: ACEI users (only used
ACEIs during the study period), ARB users (only used
ARBs during the study period), and both drugs users (used
at least one ACEI and one ARB concurrently or subse-
quently during the study period). For each year, from 1997
through 2008, the prevalent and incident users of ACEIs,
ARBs, both drugs (ACEIs and ARBs used concurrently or
subsequently in a given year) and overall renin-angiotensin
drugs (ACEIs and ARBs used alone or in combination in a
given year) were calculated. ACEIs can be used as anexample to explain the meaning of incident and prevalent
users. Incident ACEI users in a given year were defined as
patients who received ACEIs for the first time in that year
and who did not have drug claims for ACEIs and ARBs
alone or in combination in the preceding years. Prevalent
ACEI users in a given year were defined as patients who
received ACEIs in that year. The date of birth, gender and
clinical conditions of the patients were retrieved for the
analyses. Age (in years) was determined at the earliest date
of ACEIs or ARBs prescription. The presence of cardiovas-
cular disease (CVD, ICD9-CM, 390–459), diabetes (ICD9-
CM, 249–250), kidney disease (ICD9-CM, 580–589), and
hyperlipidemia (ICD9-CM, 272) [11] was determined by
patients having at least one ICD9-CM code for the indi-
vidual diseases.
Drug utilization, expenditures and price adjustment policy
Defined daily dose (DDD) [10] was used to represent the
utilization of the investigated agents. Expenditures were
expressed in NT$. The utilization of and expenditures
on ACEIs and ARBs were expressed in months to show
longitudinal changes over time.
Seven drug price adjustments were examined, including
one based on the market price and volume survey imple-
mented on April 1, 2000 (PA2000) and six based on the
market survey in combination with generic grouping
implemented on April 1, 2001 (PA2001), March 1, 2003
(PA2003), November 1, 2004 (PA2004), September 1, 2005
(PA2005), November 1, 2006 (PA2006) and September 1,
2007 (PA2007).
Statistical analyses
Multivariate logistic regression was used to explore the
differences between ACEI users, ARB users and both
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(95% CI) were calculated.
Box-Tiao intervention analysis [12,13] was applied to de-
termine whether each price adjustment was associated with
significant changes in utilization of and expenditures on
ACEIs, ARBs and overall renin-angiotensin drugs, after
controlling for potential confounding factors. In the inter-
vention analysis, we fitted the independent variables first
and then applied the autoregressive integrated moving-
average (ARIMA) modeling identification process to the
residuals.
Therefore, we considered the following model [13,14],





þ θ Bð Þ
ϕ Bð Þ at ; for t ¼ 1; . . . ;T
where yt is the dependent variable (i.e., response series), t
is the baseline trend, denoting months in numerical order,
from 1 to T (T is the sample size), and n is the number of
price adjustments in this study. PAit is a level indicator
function to indicate whether the level changed as the ith
price adjustment occurred. That is, assuming the ith price
adjustment occurred on t ¼ t0, let PAit be 0 for t < t0, and
1 for t≥t0 . TPAit is a trend variable to indicate whether the
trend changed as the ith price adjustment occurred, that is,
let TPAit be 0 for t < t0, and t  t0 +1, for t≥t0 . β0 is the
constant term that describes the baseline level of the
dependent variable. β1 describes the baseline trend before
the first intervention occurred. β2i depicts the level change
immediately after the ith price adjustment and β2i+1 depicts
the trend change after the ith price adjustment (i.e., it com-
pares the monthly trend after the ith price adjustment with
the monthly trend before the ith price adjustment). B is the
backshift operator (i.e., BiXt ¼ Xti ). ϕ Bð Þ ¼ 1 ϕ1B
⋯ ϕpBp is the autoregressive polynomial of the model,
and θ Bð Þ ¼ 1 θ1B⋯ θqBq is the moving average
polynomial. at is the white noise with mean 0 and variance
σ2.
Dependent variables in primary analyses were the
monthly utilization of and expenditures on ACEIs, ARBs
and overall renin-angiotensin drugs. In subgroup analyses,
the monthly utilization of and expenditures on ACEIs were
categorized into patented drugs (benazepril, cilazapril, imi-
dapril, perindopril and ramipril) and off-patent drugs (cap-
topril, off-patent from PA2003; enalapril, fosinopril,
lisinopril and quinapril, off-patent from PA2006). The off-
patent ACEIs were further categorized into original
branded and generic versions. Potential independent vari-
ables included a constant (baseline level); a baseline trend;
two indicator variables for each price adjustment, namely
level change (the immediate effect) and trend change (the
long-term effect or changes over time) [14]; and threeconfounding factors. One of the three confounding factors
was the global budget system implemented in Taiwan’s
hospitals on July 1, 2002 (GB2002) that increased out-
patient use of anti-diabetic and anti-hypertensive agents
[15], and increased expenditures on all PBS listed drugs [5].
The other two confounding factors were the Chinese New
Year (CNY) [5,16] and the outbreak of severe acute respira-
tory syndrome (SARS) in 2003 [5], both of which decreased
expenditures on all PBS listed drugs. When modeling each
dependent variable, we removed a number of potential in-
dependent variables representing the cut-points of price
adjustments, and only selected some of them to incorporate
into the model (a so-called parsimonious model). These in-
dependent variables were initially selected using a backward
elimination procedure. Collinearity diagnostics were subse-
quently performed to remove variables until the condition
index was less than 30 [13,17]. ARIMA modeling expressed
in factored form [13] was applied to the residuals. Several
candidate models were considered according to the auto-
correlation plots and partial autocorrelation plots. The
model with the minimum Akaike Information Criterion
(AIC) value was chosen as the best fit. The Ljung-Box chi-
square statistic revealed insignificant autocorrelation for the
residuals [13]. All statistical analyses were performed using




Of the 147 157 patients who met the inclusion criteria,
64 710, 22 317and 60 130 were identified as ACEI users,
ARB users and both drugs users, respectively (Table 1).
Among these patients, those aged under 60 years were
less likely to be ARB users and both drugs users than
ACEI users. Male patients were more likely to be ARB
users than ACEI users (OR= 1.08, 95% CI: 1.04–1.11),
but they were less likely to be both drugs users than
ACEI users (OR= 0.91, 95% CI: 0.89–0.93). Patients with
hyperlipidemia (OR=1.70, 95% CI: 1.64–1.77) were more
likely to take ARBs than ACEIs. Patients at risk of CVD
(OR=6.14, 95% CI: 5.54–6.81), diabetes (OR=2.04, 95% CI:
1.98–2.10), kidney disease (OR=2.96, 95% CI: 2.83–3.10),
and hyperlipidemia (OR=2.63, 95% CI: 2.56–2.71) revealed
a higher likelihood of being prescribed both drugs rather
than just ACEIs.
Figure 2a–2c depict the annual prevalent (from 1997 to
2008) and incident (from 1998 to 2008) users of overall
renin-angiotensin drugs, ACEIs, ARBs, and both drugs.
For renin-angiotensin drugs, the number of incident users
decreased from 14 848 to 10 325 (% change: -30.5%) from
1998 to 2008, while the number of prevalent users
increased from 22 049 to 72 278 (227.8%) from 1997 to
2008 (Figure 2a). For ACEIs, the number of incident users
declined from 14 104 to 4 420 (−68.7%) from 1998 to










Both drug users vs.
ACEI users}Adjusted
OR (95%CI)
Age†, mean (SD) 54.7(17.1) 57.8(14.0) 59.7(12.8)
< 20 yrs 2,657(4.1) 71(0.3) 102(0.2) 0.13(0.10–0.17)# 0.19(0.15–0.23)#
20–39 yrs 7,197(11.1) 1,910(8.6) 3,532(5.9) 0.81(0.77–0.86)# 0.60(0.57–0.63)}
40–59 yrs 28,172(43.5) 10,534(47.2) 24,565(40.9) 0.99(0.96–1.02)# 0.72(0.71–0.74)#
>= 60 yrs (reference group) 26,684(41.2) 9,802(43.9) 31,931(53.1) 1 1
Sex
Male 33,267(51.4) 11,984(53.7) 29,810(49.6) 1.08(1.04–1.11)# 0.91(0.89–0.93)#
Female (reference group) 31,433(48.6) 10,333(46.3) 30,320(50.4) 1 1
Clinical conditions{
Cardiovascular disease (CVD) risk (390–459) 55,253(85.4) 20,526(92.0) 59,489(98.9) 0.63(0.57–0.68)# 6.14(5.54–6.81)#
Diabetes (249–250) 11,595(17.9) 4,837(21.7) 24,311(40.4) 0.93(0.90–0.97)} 2.04(1.98–2.10)#
Kidney diseases (580–589) 3,493(5.4) 1,215(5.4) 9,863(16.4) 0.84(0.79–0.91)# 2.96(2.83–3.10)#
Hyperlipidemia (272) 11,247(17.4) 6,353(28.5) 26,004(43.2) 1.70(1.64–1.77)# 2.63(2.56–2.71)#
None of the above diseases 7,745(12.0) 841(3.8) 113(0.2) 0.28(0.25–0.31)# 0.21(0.17–0.26)#
*Unless otherwise indicated, values are numbers and proportions (in %).
†Age is defined at the earliest date of ACEIs or ARBs prescription.
{The clinical conditions were represented by ICD9-CM codes.
}The adjusted odds ratios were estimated in multivariate logistic regression with the reference group defined as patients who were treated only with ACEIs during
the study period. Patients who were treated only with ARBs were defined as ARB users. Patients who were treated with at least one ACEI and one ARB during the
study period were defined as both drug users.
}Significance is represented as: p< 0.01, #p< 0.0001.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; OR, odds ratio; SD, standard deviation.
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22 049 to 29 949 (35.8%) from 1997 to 2005 and declined
from 29 949 to 24 369 (−18.6%) from 2005 to 2008. For
ARBs, the number of incident users increased from 399 to
4 704 (1078.9%), and the number of prevalent users
increased from 498 to 38 758 (7682.7%) from 1998 to
2008 (Figure 2b). For users of both drugs, the number of
incident users increased from 345 to 1 201 (248.1%) and
the number of prevalent users increased from 811 to 9 151
(1028.4%) from 1998 to 2008 (Figure 2c). It is noteworthy
that the number of prevalent ARB users increased rapidly
between 1998 and 2008, and has exceeded the number of
prevalent ACEI users since 2007. However, the number of
incident ARB users only increased slightly year by year
(Figure 2b), and the number of cumulative incident ARB
users (from 1998 to a given year) was always less than the
number of prevalent ARB users in each year, with the
former only being 60 to 80% of the latter (Figure 2d). This
indicates that annual prevalent ARB users were not only
from the category of cumulative incident ARB users, but
also included users who initially used ACEIs, or both
drugs, in preceding years and switched to ARBs thereafter.
Drug utilization
The baseline level of utilization of ACEIs was 232 380
DDD and increased by 5 531 DDD (p< 0.0001) per
month from January 1997. There was an immediatedecrease of 48 286 DDD (level change: -20.8%, p
< 0.0001) when PA2000 was implemented, but an immedi-
ate increase of 28 987 DDD (level change: 15.7%,
p=0.0073) following PA2004. ACEIs long-term increasing
trend decreased to 671 DDD per month after the imple-
mentation of PA2004 (trend change: -87.9%, p< 0.0001)
and turned to a long-term decreasing trend of 2 858 DDD
per month after the implementation of PA2006 (trend
change: -525.9%, p=0.0002), diminishing to 691 742 DDD
in December 2008 (Figure 3a and Table 2). In subgroup
analyses, we observed that the utilization of off-patent
ACEIs showed a similar trend to that of ACEIs, but the
baseline increasing trend turned to a downward trend even
earlier following PA2004. On the other hand, the
utilization of patented ACEIs showed an increasing trend
throughout the study period (Figure 3b and Table 2).
When off-patent ACEIs were further categorized into ori-
ginal branded and generic versions, we found that the
baseline increasing trend for the utilization of original
branded version turned to a decreasing trend after the im-
plementation of PA2004. Generic versions still showed an
upward trend at PA2004 and only turned to a downward
trend afterward when PA2005 was implemented (Figure 3c
and Table 2).
Unlike ACEIs, a long-term increasing trend in the
utilization of ARBs and overall renin-angiotensin drugs
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Figure 2 The number of annual incident and prevalent users for ACEIs and ARBs. (a) Annual incident and prevalent users of
renin-angiotensin drugs (ACEIs and/or ARBs); (b) Annual incident and prevalent users of ACEIs or ARBs; (c) Annual incident and prevalent users of
both drugs (i.e., ACEIs and ARBs used concurrently or subsequently); (d) Annual prevalent ARB users and cumulative incident ARB users. ACEIs,
angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers.
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was zero and increased by 5 044 DDD (p< 0.0001) per
month from February 1998. Following PA2003, the long-
term increasing trend of the use of ARBs further
increased to 10 058 DDD per month (trend change: 99.4%,
p< 0.0001). When PA2007 was implemented, ARBs long-
term increasing trend further increased to 18 041 DDD
per month (trend change: 85.3%, p=0.0003), reaching 1
157 724 DDD in December 2008. The baseline level of the
utilization of overall renin-angiotensin drugs was 135 289
DDD, and utilization showed a long-term increasing trend
of 12 027 DDD (p< 0.0001) per month from January
1997. When PA2000 was implemented, overall usage
experienced an immediate decrease of 73 794 DDD (level
change: -54.5%, p=0.0053). However, throughout the
study period, the long-term increasing trend in the
utilization of overall renin-angiotensin drugs was not
influenced by any price adjustment, reaching 1 817 084
DDD in December 2008 (Figure 3a and Table 2).With regard to the three confounding factors, only
CNY significantly resulted in immediate decreases in the
utilization of ACEIs (including in subgroup analyses),
ARBs and overall renin-angiotensin drugs (Table 2).
Drug expenditures
The baseline level of expenditures on ACEIs was 4 509
908 NT$ and increased by 66 568 NT$ (p< 0.0001) per
month from January 1997. The expenditures on ACEIs
experienced an immediate decrease of 592 252 NT$
(level change: -13.1%, p= 0.0151) and 1 255 287 NT$
(level change: -32.0%, p< 0.0001), respectively, following
PA2000 and PA2003. The long-term increasing trend in
ACEI expenditures turned to a downward trend of 30
014 NT$ per month after the implementation of PA2004
(trend change: -145.1%, p< 0.0001). When PA2006 was
implemented, ACEI expenditures showed an immediate
decrease of 1 545 767 NT$ (level change: -58.1%,
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GB2002 SARS
Figure 3 Monthly utilization of ACEIs, ARBs, and overall renin-angiotensin drugs. (a) ACEIs, ARBs and renin-angiotensin drugs; (b) patented
and off-patent ACEIs; (c) original branded and generic off-patent ACEIs. The arrows indicate the time points at which price adjustments were
implemented. ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; DDD, defined daily dose; PA2000, price
adjustment implemented on April 1, 2000; PA2001, price adjustment implemented on April 1, 2001; PA2003, price adjustment implemented on
March 1, 2003; PA2004, price adjustment implemented on November 1, 2004; PA2005, price adjustment implemented on September 1, 2005;
PA2006, price adjustment implemented on November 1, 2006; PA2007, price adjustment implemented on September 1, 2007.
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to 5 527 281 NT$ in December 2008 (Figure 4a and
Table 3). In subgroup analyses, we observed that expen-
ditures on off-patent ACEIs showed a similar trend to
that of ACEIs overall. The baseline increasing trend also
turned to a decreasing trend following PA2004, but
experienced an additional level reduction following
PA2007. On the other hand, expenditures on patented
ACEIs showed an increasing trend throughout the
study period (Figure 4b and Table 3). When off-patent
ACEIs were further categorized into original branded
and generic versions, we found that expenditures on
off-patent original branded ACEIs showed a similar
trend to off-patent ACEIs. Expenditures on off-patent
generic ACEIs only showed an immediate decrease
when PA2003, PA2006 and PA2007 were implemented,
but was not influenced by any price adjustment in the
long term (Figure 4c and Table 3).Unlike ACEIs, expenditures on ARBs revealed a long-
term increasing trend from 1998 to 2008. The baseline level
of expenditures on ARBs was zero and increased by a trend
of 92 537 NT$ (p< 0.0001) per month from February
1998. Following PA2001, the long-term increasing trend of
expenditures on ARBs increased to 253 009 NT$ per
month (trend change: 173.4%, p< 0.0001). When PA2004
was implemented, the long-term increasing trend
decreased to 132 671 NT$ per month (trend change:
-47.6%, p=0.0003), but following PA2007, the long-term
upward trend further increased to 326 714 NT$ (trend
change: 146.3%, p< 0.0001), reaching 24 228 254 NT$ in
December 2008. The baseline level of expenditures on
overall renin-angiotensin drugs was 3 753 898 NT$ and
increased with a trend of 152 800 NT$ (p< 0.0001) per
month from January 1997. When PA2001 was imple-
mented, the long-term increasing trend increased to 263
059 NT$ per month (trend change: 72.2%, p< 0.0001),
Table 2 Impact of price adjustments on monthly utilization of ACEIs, ARBs and overall renin-angiotensin drugs
Dependent variables Time period Factored ARIMA model* Independent variables† Coefficients‡ p value
Primary analyses
ACEIs Jan 1997 to Dec 2008 p = (6); Constant 232,380 <0.0001
q = (6)(12) Baseline trend 5,531 <0.0001
PA2000 level change -48,286 <0.0001
PA2004 level change 28,987 0.0073
PA2004 trend change -4,860 <0.0001
PA2006 trend change -3,529 0.0002
CNY -36,256 <0.0001
ARB Feb 1998 to Dec 2008 p = (2,3)(12) Baseline trend 5,044 <0.0001
PA2003 trend change 5,014 <0.0001
PA2007 trend change 8,583 0.0003
CNY -21,476 0.0219
Renin-angiotensin drugs Jan 1997 to Dec 2008 p = (2,5)(12) Constant 135,289 <0.0001
Baseline trend 12,027 <0.0001
PA2000 level change -73,794 0.0053
CNY -32,789 0.0371
Subgroup analyses for ACEIs
Patented ACEIs Jan 1997 to Dec 2008 p = (6); Constant 18,039 <0.0001
q = (6) Baseline trend 872 <0.0001
PA2000 level change -9,466 <0.0001
PA2001 level change 6,416 0.0022
PA2004 trend change 1,235 <0.0001
PA2005 level change -13,602 <0.0001
CNY -7,318 <0.0001
Off-patent ACEIs Jan 1997 to Dec 2008 p = (12); Constant 209,374 <0.0001
q = (9) Baseline trend 4,617 <0.0001
PA2000 level change -37,219 <0.0001
PA2004 level change 26,145 0.0028
PA2004 trend change -5,201 <0.0001
PA2006 trend change -4,593 <0.0001
CNY -20,665 0.0021
Off-patent original branded ACEIs Jan 1997 to Dec2008 p = (1,4,5)(12) Constant 179,478 <0.0001
Baseline trend 527 0.0081
PA2000 level change -21,380 0.0031
PA2004 trend change -2,574 <0.0001
CNY -11,501 0.0003
Off-patent generic ACEIs Jan 1997 to Dec 2008 p = (12); Constant 25,416 <0.0001
q = (12) Baseline trend 4,205 <0.0001
PA2000 level change -23,138 <0.0001
PA2004 level change 22,925 <0.0001
PA2005 trend change -4,315 <0.0001
PA2006 trend change -3,197 <0.0001
CNY -9,447 0.0445
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Table 2 Impact of price adjustments on monthly utilization of ACEIs, ARBs and overall renin-angiotensin drugs
(Continued)
*Factored ARIMA model is represented by p, d, q: p, auto-regressive order; d, differencing order; q, moving-average order; seasonal order is represented by p = (12),
d = (12) or q = (12). Take ACEIs as an example. The moving-average operator represented by q = (6)(12) means(1-θ6B
6) (1-θ12B
12).
†Parsimonious models were adopted, and therefore, only significant independent variables were incorporated into the model.
‡The unit of the regression coefficient is defined daily dose (DDD).ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blocker; ARIMA,
auto-regressive integrated moving-average;CNY, Chinese new year; PA2000, price adjustment implemented on April 1, 2000; PA2001, price adjustment
implemented on April 1, 2001; PA2003, price adjustment implemented on March 1, 2003; PA2004, price adjustment implemented on November 1, 2004; PA2005,
price adjustment implemented on September 1, 2005; PA2006, price adjustment implemented on November 1, 2006; PA2007, price adjustment implemented on
September 1, 2007.
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decreased to 129 734 NT$ per month (trend change:
-50.7%, p< 0.0001). When PA2006 was implemented,
the expenditures on overall renin-angiotensin drugs
showed an immediate decrease of 2 224 884 (level
change: -59.3%, p< 0.0001). Expenditures still main-
tained a long-term increasing trend of 129 734 NT$ per
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Figure 4 Monthly expenditures on ACEIs, ARBs, and overall renin-ang
patented and off-patent ACEIs; (c) original branded and generic off-patent
were implemented. ACEIs, angiotensin-converting enzyme inhibitors; ARBs,
exchange rate of NT$30.39 to US$1 on June 30, 2008); PA2000, price adjust
implemented on April 1, 2001; PA2003, price adjustment implemented on
2004; PA2005, price adjustment implemented on September 1, 2005; PA200
adjustment implemented on September 1, 2007.trend further increased to 302 790 NT$ per month (trend
change: 133.4%, p< 0.0001), reaching 30 201 508 NT$ in
December 2008 (Figure 4a and Table 3).
With regard to the three confounding factors, only
CNY significantly resulted in immediate decreases in the
expenditures on ACEIs (except for off-patent generic
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GB2002 SARS
iotensin drugs. (a) ACEIs, ARBs and renin-angiotensin drugs; (b)
ACEIs. The arrows indicate the time points at which price adjustments
angiotensin receptor blockers; NT$, New Taiwan Dollars (at an
ment implemented on April 1, 2000; PA2001, price adjustment
March 1, 2003; PA2004, price adjustment implemented on November 1,
6, price adjustment implemented on November 1, 2006; PA2007, price
Table 3 Impacts of price adjustments on monthly expenditures on ACEIs, ARBs and overall renin-angiotensin drugs
Dependent variables Time period Factored ARIMA model* Independent variables† Coefficients‡ p value
Primary analyses
ACEIs Jan 1997 to
Dec 2008
p = (1)(12); Constant 4,509,908 <0.0001
q = (1)(9) Baseline trend 66,568 <0.0001
PA2000 level change -592,252 0.0151
PA2003 level change -1,255,287 <0.0001
PA2004 trend change -96,582 <0.0001
PA2006 level change -1,545,767 <0.0001
CNY -351,216 0.0029
ARB Feb 1998 to
Dec 2008
p = (12); Baseline trend 92,537 <0.0001
q = (2) PA2001 trend change 160,472 <0.0001
PA2004 trend change -120,338 <0.0001
PA2007 trend change 194,043 <0.0001
CNY -577,052 0.0220
Renin-angiotensin drugs Jan 1997 to
Dec 2008
p = (6); Constant 3,753,898 <0.0001
q = (6) Baseline trend 152,800 <0.0001
PA2001 trend change 110,259 <0.0001
PA2004 trend change -133,325 <0.0001
PA2006 level change -2,224,884 <0.0001
PA2007 trend change 173,056 <0.0001
CNY -1,108,357 0.0011
Subgroup analyses for ACEIs
Patented ACEIs Jan 1997 to
Dec 2008
p = (1)(6,12); Constant 497,488 <0.0001
q = (1) Baseline trend 12,684 <0.0001
PA2001 level change 189,675 0.0281
PA2007 trend change 25,478 0.0088
CNY -116,498 0.0011
Off-patent ACEIs Jan 1997 to
Dec 2008
p = (1)(12); Constant 3,987,107 <0.0001
q = (1)(9) Baseline trend 45,221 <0.0001
PA2000 level change -380,037 0.0251
PA2003 level change -1,022,868 <0.0001
PA2004 trend change -70,970 <0.0001
PA2006 level change -1,675,618 <0.0001






p = (1)(12); Constant 3,195,426 <0.0001
q = (1)(9) Baseline trend 12,121 0.0081
PA2000 level change -266,177 0.0271
PA2003 level change -498,038 <0.0001
PA2004 trend change -46,182 <0.0001






p = (1)(12); Constant 985,881 0.0269
q = (1)(5,9) Baseline trend 27,153 0.0008
PA2003 level change -525,353 <0.0001
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Table 3 Impacts of price adjustments on monthly expenditures on ACEIs, ARBs and overall renin-angiotensin drugs
(Continued)
PA2006 level change -1,092,328 <0.0001
PA2007 level change -524,951 <0.0001
*Factored ARIMA model is represented by p, d, q: p, auto-regressive order; d, differencing order; q, moving-average order; seasonal order is represented by p = (12),




†Parsimonious models were adopted, and therefore, only significant independent variables were incorporated into the model.
‡The unit of the regression coefficient is NT$ (NT$, New Taiwan Dollars; at an exchange rate of NT$30.39 to US$1 on June 30, 2008)
ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blocker; ARIMA, auto-regressive integrated moving-average;
CNY, Chinese new year; PA2000, price adjustment implemented on April 1, 2000; PA2001, price adjustment implemented on April 1, 2001; PA2003, price
adjustment implemented on March 1, 2003; PA2004, price adjustment implemented on November 1, 2004; PA2005, price adjustment implemented on September
1, 2005; PA2006, price adjustment implemented on November 1, 2006; PA2007, price adjustment implemented on September 1, 2007.
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There are two major findings in our study. One is that
the increase in prevalent ARB users is associated with
switching from being an ACEI user. This result is con-
sistent with the long-term trend increases in utilization
of ARBs, but a long-term trend decrease in utilization of
ACEIs. The other is that the increase in expenditures on
renin-angiotensin drugs throughout this study primarily
resulted from increases in the number of incident ARB
users and potential switching from ACEIs to ARBs, but
not from changes in the use of overall renin-angiotensin
drugs. Ultimately, cost savings have not been achieved in
overall use of renin-angiotensin drugs. Our findings differ
from those of previous studies that showed cost savings in
pharmaceutical expenditures for all PBS listed drugs [5]
and generic substitution driven by the financial incentive
for physicians [6] after price adjustments.
As mentioned, a feature of Taiwan’s health care system
is that physicians both prescribe and dispense drugs be-
cause they are permitted by Taiwan’s Department of
Health to hire pharmacists to work at their on-site phar-
macies [2]. Physicians stand to profit from the gap be-
tween the reimbursement price and the market trading
price. In 2009, Liu et al. [6] conducted a study in Taiwan
to investigate prescribing preferences between original
branded and generic drugs in relation to this potential
profit margin, and found that prescribing of generics
increased as the reimbursement price decreased. Our
results were only consistent with these findings when we
examined the change in utilization of off-patent ACEIs.
We observed that the utilization of off-patent original
branded ACEIs was lower than that of off-patent generic
ACEIs since 2001. Although the initial upward trend in
the use of off-patent generic ACEIs turned to a decreasing
trend after the implementation of PA2005, the use of these
drugs is still higher than that of off-patent original branded
drugs. However, our findings differ to those of Liu et al.
when looking at both ACEIs and ARBs. Since these two
classes of drugs work through the same renin-angiotensin
pathway and have a similar effect in cardiovascular disease
and renal protection [7], physicians make a prescribing de-
cision between ACEIs and ARBs when the patient needs arenin-angiotensin drugs. We observed that, following
PA2006, the initial rising trend of the use of ACEIs turned
to a decreasing trend, primarily due to the decreases in
the use of off-patent ACEIs. The initial rising trend of
the use of ARBs further increased following PA2003 and
PA2007, and the use of ARBs exceeded that of ACEIs
from 2007. In fact, the profit margin from patented and
off-patent drugs varies over time, depending on when a
drug turned from patented (applying WAP adjustment)
to off-patent (applying GWAP adjustment) as well as
the value of the r-zone (the accessible profit margin for
physicians) imposed by the BNHI. Because the extent of
WAP adjustment for patented drugs is smaller than that
of the GWAP adjustment for off-patent drugs, and be-
cause the r-zone is larger for patented drugs than for off-
patent drugs, patented drugs offer higher financial incen-
tive to physicians through stepwise price adjustments.
Another study conducted by Lee et al. [5] addressed
the issue of Taiwan’s cost containment strategies on
pharmaceutical expenditures. The authors of that study
also applied Box-Tiao intervention analysis to examine
the level change (the immediate effect) after the imple-
mentation of drug price adjustments. They found that
pharmaceutical expenditures on all PBS listed drugs sig-
nificantly decreased after the introduction of price
adjustments based on generic grouping (PA2001 and
PA2003). Our study included a time trend variable in the
model, which enabled us to investigate the long-term
effects of price adjustments. In fact, we found that the
long-term trend in expenditures on overall renin-angio-
tensin drugs increased after PA2001 and PA2007.
Exploring increases in expenditures on overall
renin-angiotensin drugs, we found that annual incident
renin-angiotensin drug users declined over time, and no
significant trend increases were found in the utilization
of renin-angiotensin drugs over the study period. We
also found that annual incident ARB users and annual
prevalent ARB users increased over time. In particular,
the annual prevalent ARB users always exceeded the
number of cumulative incident ARB users, indicating
that annual prevalent ARB users were not only from the
category of cumulative incident ARB users, but also
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ings suggest that the increase in expenditures on renin-
angiotensin drugs throughout this study primarily
resulted from increases in the number of incident ARB
users and potential switching from ACEIs to ARBs, but
not from changes in the use of overall renin-angiotensin
drugs.
Although the health care systems in Canada and
European countries are different from that in Taiwan,
and the reference pricing (RP) scheme [18] adopted in
these countries control cost from the demand side
(patients) but not from the providers (physicians) side,
some of the studies conducted reveal that the RP scheme
did not have any long-term effects. Evidence from the
Netherlands showed that, after the implementation of the
RP scheme, the cost of drugs covered by the RP scheme
increased less than predicted, but the cost of drugs outside
of the RP scheme has increased annually [19]. In addition,
evidence from Germany and Hungary showed that
pharmaceutical expenditures are still not well controlled
because of volume growth that occurred after the imple-
mentation of the RP scheme [20,21].
Previous studies have reported that the use of cheaper,
generic drugs may lead to cost savings, but clinical con-
cerns regarding patient safety and therapeutic effective-
ness related to treatment discontinuation have also been
raised [22-25]. Our study demonstrated that prescription
switching was from cheaper drugs to more expensive
agents, and our patients, with a complexity of clinical
conditions, were more likely to be treated with both
drugs (subsequent or concurrent use of ACEI and ARB)
than ACEIs alone. It is noteworthy that a difference be-
tween ARBs and ACEIs may be the persistent coughing
caused by ACEIs. Patients who cannot tolerate ACEIs often
switch to ARBs. No differences in the clinical recommen-
dations for ARBs and ACEIs were noted during the study
period [7]. Further analyses are warranted to compare the
effectiveness and economic outcome for patients treated
with ACEIs, those treated with ARBs, and those who
switched from ACEIs to ARBs.
This study had several limitations. First, the baseline
disease severity which led to initiation of treatment with
ACEIs or ARBs was not compared, and we were unable
to distinguish the clinical appropriateness of stopping or
switching drugs for individual patients. The assessment
of clinical conditions using ICD9-CM codes is likely to
minimize most, but not all, of the potential bias. Second,
there was no control group in this study, because price
adjustments were implemented nationwide concurrently.
However, the time points in the pre-intervention period
served as a control group for the post-intervention period
in the intervention analysis. Thus, issues regarding internal
validity (such as history and maturation) were taken into
consideration [14]. Finally, because the time periodbetween price adjustments is quite short, incorporating
each price adjustment’s level change and trend change into
the intervention model would show severe multicollinear-
ity, and it would be difficult to achieve significance for the
collinearity parameters. That is why some previous studies
only examined the level change, but not the trend change.
However, since the trend change represents the long-term
effect of policy interventions, its implication is greater than
what the level change can explain and so it cannot be
ignored. Therefore, we adopted a parsimonious model in-
stead of a full model [14], keeping only the significant pre-
dictors selected by a backward elimination procedure and
collinearity diagnostics. In this way, the long-term effect of
the price adjustments can be examined and the multicolli-
nearity problem can be avoided.
Conclusions
The implementation of Taiwan’s stepwise price adjust-
ments, with different adjustment strategies applied to
patented and off-patent drugs, has achieved cost savings
for off-patent ACEIs, but not for patented ACEI, ARBs
and overall renin-angiotensin drugs in the long term.
Increases in incident ARB users and possible switching
from ACEIs to ARBs have emerged. These results indi-
cate that policy makers in Taiwan should reconsider the
appropriateness of the current adjustment strategies ap-
plied to patented and off-patent products, since they re-
sult in a difference in the profit margin that physicians
obtain from these two classes of drugs and affect physi-
cians’ prescribing decisions.
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